Ryan D Roberts, MD, PhD

College

College of Medicine

Department/Division

Pediatrics

Academic Title

Asst Professor

Research Program

Translational Therapeutics

614-722-2996

614-722-5895

roberts.669@osu.edu;REGINA.ROBERTS@OSUMC.EDU

Publications

Osteosarcoma: Accelerating Progress Makes for a Hopeful Future.

Saraf AJ, Roberts RD, Fenger JM

Front Oncol 8 4 01/01/2018
Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.

Choi K, Finlay JL, Yeager ND, Haworth KB, Ratner N, Arnold MA, Pierson CR, Roberts RD, Cripe TP

Oncotarget 8 82037-82048 10/10/2017
Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: Implications for immunotherapy.

Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N, Roberts RD, Finlay JL, Cripe TP

Oncotarget in press 05/30/2017
Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA

PLoS One 12 e0181885 01/01/2017

See Full List

Back to Researcher Search

Find a Researcher
Find a Clinical Trial

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

By Name or Keyword

OR

By Research Program

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

Ryan D Roberts, MD, PhD

College

Department/Division

Academic Title

Research Program

Publications

Osteosarcoma: Accelerating Progress Makes for a Hopeful Future.

Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.

Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: Implications for immunotherapy.

Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

OR

OR

Search for Clinical Trials

Find a Scientific Publication

Ryan D Roberts, MD, PhD

College

Department/Division

Academic Title

Research Program

Publications

Osteosarcoma: Accelerating Progress Makes for a Hopeful Future.

Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.

Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: Implications for immunotherapy.

Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

Related Links

OR

OR

Search for Clinical Trials

Find a Scientific Publication